Liver transplantation: An appraisal of the present situation

Digestive Diseases

Volumn 31, Issue 1, 2013, Pages 164-169

  Otto, Gerd ^a  

^a UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

Author keywords

Allocation; Indication; Liver transplantation; Outcome

Indexed keywords

ANTIVIRUS AGENT; AZATHIOPRINE; CALCINEURIN INHIBITOR; CYCLOSPORIN; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MYCOPHENOLIC ACID; STEROID; TACROLIMUS;

ACUTE LIVER FAILURE; ANTIVIRAL THERAPY; CANCER SURGERY; CHOLESTASIS; CONFERENCE PAPER; DIABETES MELLITUS; DIARRHEA; GINGIVA HYPERPLASIA; GRAFT SURVIVAL; HEPATIC ARTERY THROMBOSIS; HEPATITIS B; HEPATITIS C; HIRSUTISM; HUMAN; HYPERLIPIDEMIA; IMMUNOSUPPRESSIVE TREATMENT; LEUKOPENIA; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER GRAFT REJECTION; LIVER TOXICITY; LIVER TRANSPLANTATION; MEDICAL ETHICS; MUSCLE HYPERTONIA; NEPHROTOXICITY; NEUROTOXICITY; PORTAL VEIN THROMBOSIS; POSTOPERATIVE THROMBOSIS; PRIORITY JOURNAL; RETRANSPLANTATION; SURGICAL MORTALITY; THROMBOCYTOPENIA;

EID: 84879597569     PISSN: 02572753     EISSN: 14219875     Source Type: Journal    
DOI: 10.1159/000347213     Document Type: Conference Paper

References (21)

1. European Transplant Registry P. 2012. http://www.eltr.org/.
2. Collaborative Transplant Study H, Germany. 2012. http://www.ctstransplant.org/.
3. Yeh H, Smoot E, Schoenfeld DA, Markmann JF: Geographic inequity in access to livers for transplantation. Transplantation 2011; 91: 479-486.
4. Eurotransplant International Foundation. http://www.eurotransplant.org/cms/.
5. Duffy JP, Hong JC, Farmer DG, Ghobrial RM, Yersiz H, Hiatt JR, et al: Vascular complications of orthotopic liver transplantation: experience in more than 4, 200 patients. J Am Coll Surg 2009; 208: 896-903.
6. Op den Dries S, Sutton ME, Lisman T, Porte RJ: Protection of bile ducts in liver transplantation: looking beyond ischemia. Transplantation 2011; 92: 373-379.
7. Buis CI, Geuken E, Visser DS, Kuipers F, Haagsma EB, Verkade HJ, et al: Altered bile composition after liver transplantation is associated with the development of nonanastomotic biliary strictures. J Hepatol 2009; 50: 69-79.
8. Hansen T, Hollemann D, Pitton MB, Heise M, Hoppe-Lotichius M, Schuchmann M, et al: Histological examination and evaluation of donor bile ducts received during orthotopic liver transplantation-a morphological clue to ischemic-type biliary lesion? Virchows Arch 2012; 461: 41-48.
9. Sanchez-Urdazpal L, Gores GJ, Ward EM, Maus TP, Buckel EG, Steers JL, et al: Diagnostic features and clinical outcome of ischemictype biliary complications after liver transplantation. Hepatology 1993; 17: 605-609.
10. Blok JJ, Braat AE, Adam R, Burroughs AK, Putter H, Kooreman NG, et al: Validation of the donor risk index in orthotopic liver transplantation within the Eurotransplant region. Liver Transpl 2012; 18: 112-119.
11. Berenguer M, Royuela A, Zamora J: Immunosuppression with calcineurin inhibitors with respect to the outcome of HCV recurrence after liver transplantation: results of a metaanalysis. Liver Transpl 2007; 13: 21-29.
12. Zimmermann T, Bocher WO, Biesterfeld S, Zimmermann A, Kanzler S, Greif-Higer G, et al: Efficacy of an escalating dose regimen of pegylated interferon alpha-2a plus ribavirin in the early phase of HCV reinfection after liver transplantation. Transpl Int 2007; 20: 583-590.
13. Watt KD, Lyden ER, McCashland TM: Poor survival after liver retransplantation: is hepatitis C to blame? Liver Transpl 2003; 9: 1019-1024.
14. Werner CR, Egetemeyr DP, Lauer UM, Nadalin S, Konigsrainer A, Malek NP, et al: Telaprevir-based triple therapy in liver transplanted HCV patients: a 12-week pilot study providing safety and efficacy. Liver Transpl 2012; 18: 1464-1470.
15. Mazzaferro V, Regalia E, Doci R, Andreola S, Pulvirenti A, Bozzetti F, et al: Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996; 334: 693-699.
16. Mazzaferro V, Llovet JM, Miceli R, Bhoori S, Schiavo M, Mariani L, et al: Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. Lancet Oncol 2009; 10: 35-43.
17. Gordon-Weeks AN, Snaith A, Petrinic T, Friend PJ, Burls A, Silva MA: Systematic review of outcome of downstaging hepatocellular cancer before liver transplantation in patients outside the Milan criteria. Br J Surg 2011; 98: 1201-1208.
18. Weber ML, Ibrahim HN, Lake JR: Renal dysfunction in liver transplant recipients: evaluation of the critical issues. Liver Transpl 2012; 18: 1290-1301.
19. Schaubel DE, Guidinger MK, Biggins SW, Kalbfleisch JD, Pomfret EA, Sharma P, et al: Survival benefit-based deceased-donor liver allocation. Am J Transpl 2009; 9: 970-981.
20. Wiesner RH, McDiarmid SV, Kamath PS, Edwards EB, Malinchoc M, Kremers WK, et al: MELD and PELD: application of survival models to liver allocation. Liver Transpl 2001; 7: 567-580.
21. Dutkowski P, Oberkofler CE, Slankamenac K, Puhan MA, Schadde E, Mullhaupt B, et al: Are there better guidelines for allocation in liver transplantation? A novel score targeting justice and utility in the model for end-stage liver disease era. Ann Surg 2011; 254: 745-753.